cyamemazine cyamemazine cyamemazine (tercian), also known as cyamepromazine, is a typical antipsychotic drug of the phenothiazine class which was introduced by theraplix in france in 1972 and later in portugal as well. cyamemazineclinical datatrade namestercianahfs/drugs.cominternational drug namesroutes ofadministrationoral, im, ivatc coden05aa06 (who) legal statuslegal status in general: ℞ (prescription only) pharmacokinetic databioavailability10-70%metabolismhepaticelimination half-life10 hoursexcretionurineidentifiers iupac name 10-(3-dimethylamino-2-methyl-propyl)phenothiazine-2-carbonitrile cas number3546-03-0 ypubchem cid62865iuphar/bps84drugbankdb09000 nchemspider56597 yuniia2jgv5cnu4keggd07307 ychemblchembl2104153 necha infocard100.020.541 chemical and physical dataformulac19h21n3smolar mass323.46 g·mol−13d model (jsmol)interactive image smiles n#cc2cc1n(c3c(sc1cc2)cccc3)cc(c)cn(c)c inchi inchi=1s/c19h21n3s/c1-14(12-21(2)3)13-22-16-6-4-5-7-18(16)23-19-9-8-15(11-20)10-17(19)22/h4-10,14h,12-13h2,1-3h3 ykey:slfgioiongjgrt-uhfffaoysa-n y ny (what is this?) (verify) medical use it is used for the treatment of schizophrenia and, especially, for psychosis-associated anxiety, due to its unique anxiolytic efficacy. it is also used to reduce anxiety associated with benzodiazepine withdrawal syndrome and anxiety in depression with suicidal tendency. side effects here are some of the most common side effects and related incidence: sedation (20%) vertigo (7.9%) constipation (4%) dyskinesia (4.4%) dryness of mouth (5.9%) hypotension (7.4%) tachycardia (3.2%) mechanism cyamemazine differs from other phenothiazine neuroleptics in that aside from the usual profile of dopamine, α1-adrenergic, h1, and mach receptor antagonism, it additionally produces potent blockade of several serotonin receptors, including 5-ht2a, 5-ht2c, and 5-ht7. these actions have been implicated in cyamemazine's anxiolytic effects (5-ht2c) and lack of extrapyramidal side effects (5-ht2a), and despite being classified as a typical antipsychotic, it actually behaves like an atypical antipsychotic. site ki (nm) species ref h1 9.3 guinea pig h2 351 guinea pig h3 >10,000 rat m1 13 human m2 42 human m3 32 human m4 12 human m5 35 human 5-ht1a 517 human 5-ht2a 1.5 human 5-ht2c 12 human 5-ht3 2,943 human 5-ht7 22 human d1 3.8 human d2 5.8 human d3 2.5 human d4 5.3 human α1 2.3 rat α2 1320 rat gabaa >10,000 rat gabab >10,000 rat values are ki (nm). the smaller the value, the more strongly the drug binds to the site. synthesis synthesis: patent: 2-cyanophenothiazine (1) 3-chloro-2-methylpropyl(dimethyl)amine (2)